DSIP
Also known as: Delta Sleep-Inducing Peptide
DSIP is a 9-amino-acid peptide originally isolated from rabbit cerebral venous blood, claimed to support sleep architecture and stress modulation. Mechanism incompletely understood; human trial data is thin. Sold in research-chem space; community use is small.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like DSIP, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any DSIP vendor.
Not medical advice. DSIP is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
DSIP was isolated by Schoenenberger and Monnier in 1977 from cerebral venous blood of rabbits during electrically-induced sleep. The naming reflects the original observation that the fraction induced delta-wave EEG patterns. Mechanism remains incompletely characterised; proposed pathways include modulation of GABA-A receptor subunits, influence on hypothalamic-pituitary axis (some studies suggest an effect on cortisol patterns), and possible direct interaction with circadian regulators. Animal studies show effects on sleep architecture (increased slow-wave sleep), stress response, and pain perception. Human trial work has been limited and small (mostly Eastern European and Russian research from the 1980s-1990s); modern peer-reviewed trials are sparse. The compound is sold widely in the research-chem space for sleep and stress, often paired with ipamorelin in nighttime peptide stacks because GH pulses are coupled to slow-wave sleep.
Typical practice
Community practice runs 100 to 300 mcg per day, subcutaneous, dosed in the evening 30 to 60 minutes before sleep. Some users dose intranasal at higher concentrations because the compound is sometimes formulated for nasal delivery. Reconstitution: 5 mg vial in 5 mL bacteriostatic water for 1 mg/mL concentration; the calculator at panya.health/tools/reconstitution-calculator handles the dose math. Cycles vary; some users dose nightly indefinitely, others run 4 to 8 week cycles with breaks. The honest answer on dose-finding is that human dose-response data simply does not exist at the resolution we have for established sleep medications; community practice is extrapolated from animal work and self-titration.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for DSIP in humans does not exist for most use cases listed.
Risks and contraindications
Side effect profile in published reports is mild: occasional injection site reactions, occasional reports of vivid dreams or unusual sleep architecture. No consistent cardiovascular, hepatic, or hematologic signals in the small available human literature. The mechanism may interact with sedative medications and alcohol; users on benzodiazepines, Z-drugs (zolpidem etc.), or other GABAergic agents should be cautious about additive effect. Pregnancy and breastfeeding off-limits by default. The honest read: DSIP is one of the weakest evidence bases in the peptide catalog, comparable to epitalon in the longevity space. Subjective sleep improvement reports are common but uncontrolled. Anyone with serious sleep pathology (obstructive sleep apnea, narcolepsy) should be evaluated by a sleep medicine specialist; DSIP is not a substitute for diagnosis-grade workup.
Where this stands legally
Not FDA-approved. Sold legally as a research chemical 'not for human consumption.'
Not a controlled substance. MHRA does not regulate research peptides; sale is technically lawful but human use is medically unsupervised.
Not on EMA's approved list. Treated as research chemical in member states.
TGA Schedule 4 by default for unapproved peptides. Personal-use imports actively investigated.
Not formally scheduled. Available through research-peptide channels; rare in clinical settings.
MOHAP treats unapproved peptides as prescription-only by default.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Pure RawzPending Panya 11-signal audit
- Limitless LifePending Panya 11-signal audit
- AminolabsPending Panya 11-signal audit
- Cosmic Nootropic (often paired with semax / selank)Pending Panya 11-signal audit
Full vendor scorecards for DSIP land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Schoenenberger, Monnier — Characterization of a delta-EEG-sleep-inducing peptide. Proc Natl Acad Sci, 1977 (the foundational isolation paper) →
- Sudakov et al. — Delta sleep-inducing peptide (DSIP): a review of historical research. Neurosci Behav Physiol, 1992 →
- Mendelson — A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry, 2005 (cited for context on the broader sleep-pharmacology landscape DSIP claims to operate in) →
Panya blog posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
Adjacent reading
Track DSIP in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.